环孢素A滴眼液联合氯替泼诺滴眼液治疗春季角结膜炎的疗效  被引量:8

Efficacy of cyclosporine A eye drops combined with loteprednol eye drops in treatment of vernal keratoconjunctivitis

在线阅读下载全文

作  者:尚庆丽[1] 王鑫[1] 马红蕾[1] 徐曼 

机构地区:[1]河北医科大学第二医院眼科,石家庄050000

出  处:《中国新药杂志》2017年第24期2960-2963,共4页Chinese Journal of New Drugs

摘  要:目的:观察环孢素A滴眼液对春季角结膜炎相关临床症状的疗效。方法:将60例春季角结膜炎患者随机分为试验组和对照组,每组30例,对照组患者给予氯替泼诺滴眼液治疗(剂量为每次1滴,tid,疗程为12周);试验组患者给予环孢素A滴眼液(剂量为每次1滴,qid,疗程为12周)及氯替泼诺滴眼液(剂量为每次1滴,tid,疗程为12周)联合治疗。评估患者开始治疗后4周、8周及12周的治疗效果。并按照症状及体征进行疗效评分。结果:试验组和对照组在治疗4周后总体评分均有减低,两组差异有统计学意义(P<0.05),治疗8周、12周后两组总体评分也均有减低,但差异无统计学意义(P>0.05,P>0.05)。结论:局部应用环孢素A滴眼液治疗顽固性春季角结膜炎安全有效,应鼓励局部应用环孢素A与糖皮质激素的联合使用治疗春季角结膜炎,防止并发症的产生。Objective: To investigate the clinical efficacy of cyclosporine A eye drops combined with loteprednol eye drops for treating vernal keratoconjunctivitis. Methods: Sixty vernal keratoconjunctivitis patients were randomly divided into test group (n = 30) to receive cyclosporine A eye drops (qid, one droplet once) combined with loteprednol eye drops (rid, one droplet once) and control group (n = 30) to receive loteprednol eye drops only (rid, one droplet once). The treatment course was 12 weeks. The efficacy was evaluated at week 4, 8 and 12, respectively, based on clinical symptoms and vital signs. Results: The total scores of the test group and control group both showed decrease at week 4, with statistically significant difference ( P 〈 0. 05 ). Despite decrease existed in the scores of both groups at week 8 and 12, there was no statistical difference (P 〉0.05 ,P 〉 0.05). Conclusions: Local administration of cyclosporine A is effective for treating vernal keratoconjunctivitis. cyclosporine A may be topically used in combination with to prevent the occurrence of complications. glucocorticosteroids for treating vernal keratoconjnnctivitis .

关 键 词:春季角结膜炎 环孢素A 氯替泼诺滴眼液 疗效 

分 类 号:R969.4[医药卫生—药理学] R988.1[医药卫生—药学]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象